News releases - Merck.com
Oct 28, 2024 · Merck Announces Third-Quarter 2024 Financial Results. October 28, 2024. Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC) October 24, 2024.
Merck Announces Third-Quarter 2024 Financial Results
Oct 31, 2024 · This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject ...
KOSELUGO® (selumetinib) Showed Significant and Clinically ... - Merck
1 day ago · This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject ...
Merck to Present New Data From GARDASIL®9 Studies …
1 day ago · This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private ...
MRK - | Stock Price & Latest News | Reuters
1 day ago · Get Merck & Co Inc (MRK) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments.
Merck Enters Two Strategic Collaborations to Strengthen AI …
Sep 20, 2023 · Merck, a leading science and technology company, today announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence (AI)-driven design and discovery capabilities, further advancing the company’s research efforts.
Merck (MRK) earnings Q2 2024 - CNBC
Jul 30, 2024 · Merck on Tuesday reported second-quarter revenue and adjusted earnings that topped Wall Street’s expectations as it saw strong sales from its blockbuster cancer drug Keytruda as well as other...
With 79% ownership, Merck & Co., Inc. (NYSE:MRK) boasts of …
1 day ago · The company's largest shareholder is The Vanguard Group, Inc., with ownership of 9.7%. With 8.2% and 4.6% of the shares outstanding respectively, BlackRock, Inc. and State Street Global Advisors ...
Merck buys cancer therapy developer Modifi Biosciences for up to …
Oct 23 (Reuters) - Merck (MRK.N) has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm said on...
Merck sees Gardasil China woes carrying into 2025 - Yahoo Finance
Oct 31, 2024 · MRK. By Michael Erman and Leroy Leo. (Reuters) -Merck & Co said on Thursday that weak sales of Gardasil in China are likely to carry over into 2025 as the vaccine's distributor there reduces ...
- Some results have been removed